PlaneAlert ICAO: A70E5B
Owner: ABBVIE
Flt: N554AV GA6C
Time: 2026-04-14 10:22:50 EDT
Min Alt: 18000 ft

adsb planefence planealert by kx1t - globe.adsbexchange.com/?icao=A70E5B&lat=40.625336&lon=-77.552002&showTrace=2026-04-14 sdr-e flightaware faa

Haisco Teams Up with AbbVie to Develop Innovative Pain Relief Medications Haisco Pharmaceutical Group has signed a licensing agreement with AbbVie to develop new pain therapies globally, boosting their international presence and research pipeline.

Haisco Teams Up with AbbVie to Develop Innovative Pain Relief Medications #AbbVie #pain_therapy #Haisco

AbbVie Ovarian Drug Shows 62.7% Response AbbVie's candidate posted a 62.7% response rate (Apr 12, 2026); durable follow-up, safety and confirmatory trials will determine regulatory and commercial impact.

AbbVie Ovarian Drug Shows 62.7% Response: AbbVie's candidate posted a 62.7% response rate (Apr 12, 2026); durable follow-up, safety and confirmatory trials will determine regulatory and commercial impact. 👈 Read full analysis #OvarianCancer #AbbVie #CancerResearch #Pharmaceuticals #ClinicalTrials

AbbVie Presents Promising Phase 2 Trial Data for ELAHERE® in Ovarian Cancer at SGO 2026 AbbVie introduced encouraging Phase 2 trial findings for ELAHERE®, a prospective treatment for platinum-sensitive ovarian cancer, showcasing a significant response rate at the SGO 2026 meeting.

AbbVie Presents Promising Phase 2 Trial Data for ELAHERE® in Ovarian Cancer at SGO 2026 #United_States #San_Juan #AbbVie #ELAHERE #OvarianCancer

AbbVie tries a new approach in 340B programme battle AbbVie has opened a new front in the pharma industry's battle to reform the 340B drug discounting programme for safety net hospitals in the US.

#AbbVie has opened a new front in the #pharma industry's battle to change the #340B drug discounting programme for safety net #hospitals in the US, after an early attempt was blocked in the courts.

PlaneAlert ICAO: A70E5B
Owner: ABBVIE
Flt: N554AV GA6C
Time: 2026-04-03 10:49:55 CEST
Min Alt: 30450 ft
Squawk: 2521
aircraft over heerlen - adsb planefence by kx1t - sdr-e airplanes flightaware faa

PlaneAlert ICAO: A70E5B
Owner: ABBVIE
Flt: N554AV GA6C
Time: 2026-04-03 10:49:31 CEST
Min Alt: 9085 m
Squawk: 2521
adsb planefence planealert by kx1t - sdr-e adsbexchange flightaware faa

PlaneAlert ICAO: A70E5B Tail: N554AV Flt: N554AV
Owner: AbbVie
Aircraft: Gulfstream G600
2026-04-03 10:46:50 CEST
GA6C Bizjet Biotech Pharmaceuticals
adsb planefence planealert by kx1t - wiki - adsbexchange - planefence

PlaneAlert ICAO: A70E5B
Owner: ABBVIE
Flt: N554AV GA6C
Time: 2026-04-01 18:04:31 CEST
Min Alt: 35175 ft
Squawk: 1000
aircraft over heerlen - adsb planefence by kx1t - sdr-e airplanes flightaware faa

PlaneAlert ICAO: A70E5B Tail: N554AV
Owner: AbbVie
Aircraft: Gulfstream G600
2026-04-01 18:03:26 CEST
GA6C Bizjet Biotech Pharmaceuticals
adsb planefence planealert by kx1t - wiki - adsbexchange - planefence

PlaneAlert ICAO: A70E5B
Owner: ABBVIE
Flt: N554AV GA6C
Time: 2026-04-01 17:59:53 CEST
Min Alt: 11880 m
Squawk: 1000
adsb planefence planealert by kx1t - sdr-e adsbexchange flightaware faa

AbbVie Showcases Groundbreaking Research Advancing Dermatological Care at 2026 AAD Annual Meeting AbbVie presents new clinical data related to immune-mediated skin diseases at the 2026 AAD meeting, showcasing improvements in patient outcomes.

AbbVie Showcases Groundbreaking Research Advancing Dermatological Care at 2026 AAD Annual Meeting #AbbVie #Upadacitinib #Risankizumab

CollPlant Biotechnologies' 2025 Financial Results Showcase Growth in Regenerative Medicine CollPlant Biotechnologies reveals its financial results for 2025, highlighting significant advancements in regenerative medicine and aesthetic products, while expanding its market reach.

CollPlant Biotechnologies' 2025 Financial Results Showcase Growth in Regenerative Medicine #Israel #CollPlant #rhCollagen #Rehovot #AbbVie

AbbVie’s Venetoclax Receives FDA Approval for CLL Combination Therapy AbbVie announces FDA approval for Venetoclax in combination with Acalabrutinib for untreated chronic lymphocytic leukemia, enhancing treatment options.

AbbVie’s Venetoclax Receives FDA Approval for CLL Combination Therapy #United_States #AbbVie #North_Chicago #CLL #venetoclax

AbbVie to sponsor leading US baseball league This collaboration marks the first of its kind for AbbVie and signals a massive national expansion of its ‘Striking Out Cancer’ initiative.

Can AbbVie help strike out cancer on a global scale? ⚾️

AbbVie is stepping up to the plate as Major League Baseball’s (MLB) first-ever official pharmaceutical partner, starting in the 2026 season.

Learn more: www.emjreviews.com/emj-gold/new...

#MLB #Strikeoutcancer #AbbVie

AbbVie Receives Designation for Upadacitinib as Rare Disease Treatment for Takayasu Arteritis AbbVie has secured rare disease designation for Upadacitinib targeting Takayasu arteritis, a condition with limited treatment options for patients in Japan.

AbbVie Receives Designation for Upadacitinib as Rare Disease Treatment for Takayasu Arteritis #Japan #Tokyo #AbbVie #Upadacitinib #Takayasu_Arteritis

US court says pharma giants must face False Claims suit An appeals court in the US has said AbbVie, AstraZeneca, Novartis, and Sanofi must defend claims they defrauded federal and state governments.

An #appealscourt in the #US has said that #AbbVie, #AstraZeneca, #Novartis, and #Sanofi will have to defend claims they #defrauded federal and state government programmes that supply #medicines to low-income and uninsured people.

pharmaphorum.com/news/us-cour...

Allergan Aesthetics Launches Skin Quality Index for Enhanced Aesthetic Consultations Allergan Aesthetics has unveiled the Skin Quality Index (SQI), targeting improved communication about skin quality. This initiative standardizes terms for better consultations.

Allergan Aesthetics Launches Skin Quality Index for Enhanced Aesthetic Consultations #USA #Irvine #AbbVie #Allergan_Aesthetics #Skin_Quality_Index

AbbVie Seeks Approval for Upadacitinib as Treatment for Vitiligo in Japan AbbVie applied for approval of Upadacitinib as a treatment for vitiligo in Japan, highlighting its chronic autoimmune nature and need for new therapies.

AbbVie Seeks Approval for Upadacitinib as Treatment for Vitiligo in Japan #Japan #Tokyo #AbbVie #Upadacitinib #Vitiligo

AbbVie Reveals Positive Outcomes for ABBV-295 in Weight Management Study AbbVie has announced promising results for its weight management drug ABBV-295, showing significant reductions in body weight during a Phase 1 study. Learn more here.

AbbVie Reveals Positive Outcomes for ABBV-295 in Weight Management Study #USA #Weight_Management #AbbVie #North_Chicago #ABBV-295

Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Up and Down the Ladder: Job Changes.. the latest comings & goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs #GSK #AbbVie #Takeda #AstraZeneca

Justice Department backs AbbVie in its bid to overturn a Colorado law guiding a drug discount program DOJ is backing AbbVie in its battle to overturn a Colorado law that prohibits pharmaceutical companies from placing restrictions on the 340B drug discount program.

Justice Department backs AbbVie in its bid to overturn a Colorado law guiding a drug discount program... statnews.com/pharmalot/20... #pharma #hospitals #340B #Trump #pharmacies #AbbVie

AbbVie's Ubadacitinib Receives FDA and EMA Approval for Vitiligo Treatment AbbVie has submitted an application for the approval of ubadacitinib as a treatment for adults and adolescents with vitiligo, marking a potential breakthrough in autoimmune disease therapy.

AbbVie's Ubadacitinib Receives FDA and EMA Approval for Vitiligo Treatment #United_States #AbbVie #North_Chicago #Vitiligo #Ubadacitinib

ECCO26 data reinforce long-term durability and real-world impact of AbbVie’s IBD portfolio Real-world data and three-year trial results show sustained remission and symptom control with Skyrizi and Rinvoq.

New data at ECCO 2026: Risankizumab & upadacitinib show sustained remission & real-world impact in UC & Crohn’s. Experts discuss 3-year durability, rapid symptom control & what it means for patients.
#News #ECCO26 #IBD #SKYRIZI #RINVOQ #RealWorldEvidence #AbbVie

ECCO26 data reinforce long-term durability and real-world impact of AbbVie’s IBD portfolio Real-world data and three-year trial results show sustained remission and symptom control with Skyrizi and Rinvoq.

New data at ECCO 2026: Risankizumab & upadacitinib show sustained remission & real-world impact in UC & Crohn’s. Experts discuss 3-year durability, rapid symptom control & what it means for patients.
#News #ECCO26 #IBD #SKYRIZI #RINVOQ #RealWorldEvidence #AbbVie

FDA clears first all-oral combo for first-line CLL treatment AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

The combination of #AstraZeneca's Calquence and #AbbVie / #Roche's Venclexta has become the first all-oral, fixed-duration regimen for #patients with newly-diagnosed #chroniclymphocyticleukaemia (CLL) in the #US.

AbbVie Announces Major $380 Million Investment to Enhance Pharmaceutical Production in North Chicago AbbVie is set to invest $380 million in North Chicago for the construction of two new manufacturing facilities, focusing on advanced neuroscience and obesity medications.

AbbVie Announces Major $380 Million Investment to Enhance Pharmaceutical Production in North Chicago #United_States #Active_Pharmaceutical_Ingredient #AbbVie #North_Chicago

PlaneAlert ICAO: A70E5B Tail: N554AV
Owner: AbbVie
Aircraft: Gulfstream G600
2026-02-19 15:47:19 EST
GA6C Bizjet Biotech Pharmaceuticals AsSeenonTV
adsb - wiki - adsbexchange

AbbVie Announces Quarterly Dividend as Part of Growth Strategy AbbVie Inc. has declared a quarterly cash dividend of $1.73 per share, reflecting significant growth since its inception. This dividend is payable in May, benefiting loyal shareholders.

AbbVie Announces Quarterly Dividend as Part of Growth Strategy #United_States #Dividend #AbbVie #North_Chicago #NYSE_ABBV

AbbVie Receives Approval for Aquipta to Prevent Migraine Attacks in Japan AbbVie's Aquipta, a new migraine prevention therapy, has gained marketing approval in Japan, providing a new treatment option for adults.

AbbVie Receives Approval for Aquipta to Prevent Migraine Attacks in Japan #Japan #Tokyo #AbbVie #Migraine #AQUIPTA